Previous studies have shown that KRAS activating mutation is associated with enhanced cell migration in invasion activities in many types of cancer, such as pancreatic ductal adenocarcinoma (32), prostate cancer (33), colon cancer (34, 35), and breast cancer (36). Here, KRAS is linked to prostate cancer.